Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, 52 Week, Dose-escalation Study of SP 420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

NCT03801889 is registered in ClinicalTrials.gov with Abfero Pharmaceuticals, Inc as lead sponsor.

NCT NCT03801889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03801889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, 52 Week, Dose-escalation Study of SP 420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias
Lead sponsor
Abfero Pharmaceuticals, Inc
Phase
Phase 2
Overall status
Withdrawn
Start date
August 31, 2020
Completion date
January 31, 2023
Enrollment
0 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

beta-thalassemia, iron overload